The mechanism and overcome of resistance to anti-VEGF antibody, bevacizumab in colon cancer
| Project/Area Number |
22591478
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | International University of Health and Welfare |
|---|
Principal Investigator |
TAKAHASHI Yutaka 国際医療福祉大学, 臨床医学研究センター, 教授 (10179541)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KITADAI Yashuhiko 広島大学, 大学院・医歯薬総合研究科, 准教授 (10304437)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 大腸癌外科学 / Bevacizumab / VEGF / 耐性 / colon cancer / 抗血管新生療法 / 大腸癌 |
|---|
| Research Abstract |
We studied the mechanism and overcome of resistance to anti-VEGF antibody , bevacizumab. We could not find any upregulated genes in transplanted tumors and clinical tumors which were resistant to bevacizumab while bevacizumab therapies by several microarray studies. These results suggest that the resistance to anti-VEGF would be rare rather than conventional cancer drugs and other molecular targeting drugs.
|
Report
(4 results)
Research Products
(4 results)
-
-
[Journal Article] Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301)2011
Author(s)
Komatsu Y, Takahashi Y, Kimura Y, Oda H, Tajima Y, Tamura S, Sakurai J, Wakasugi T, Tatebe S, Takahashi M, Sakata Y, Kitajima M, Sakamoto J, Saji S
-
Journal Title
Anticancer Drugs
Volume: 22(6)
Pages: 576-83
NAID
Related Report
-
-
